ResearchFutureHouse
FutureHouse's Robin agents proposed ripasudil as a dry AMD candidate; humans ran the lab tests
Robin's analysis agent reported ripasudil raised retinal cell phagocytosis 7.5-fold over controls in a lab assay; a human analysis of the same data found 1.75-fold.